A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

医学 吉西他滨 美罗华 内科学 奥沙利铂 弥漫性大B细胞淋巴瘤 肿瘤科 临床研究阶段 淋巴瘤 化疗 胃肠病学 癌症 结直肠癌
作者
Mark Hertzberg,Matthew Ku,Olivier Catalani,Betsy Althaus,Stephen J. Simko,Gareth P. Gregory
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): TPS7575-TPS7575 被引量:10
标识
DOI:10.1200/jco.2021.39.15_suppl.tps7575
摘要

TPS7575 Background: Prognosis is poor for patients with R/R DLBCL, particularly those who are ineligible for autologous stem cell transplant (ASCT) or who relapse after second-line therapy (Gisselbrecht C, et al. Br J Haematol 2018). While chimeric antigen receptor therapies have shown favorable response rates in R/R DLBCL, convenient off-the-shelf options are needed, especially for patients with rapidly progressing disease (Sermer D, et al. Blood Adv 2020). Glofitamab is a full-length, humanized, immunoglobulin G1 bispecific antibody with two regions that bind to CD20 (B cells) and one region that binds to CD3 (T cells). In an ongoing Phase I study in patients with R/R non-Hodgkin lymphoma, glofitamab monotherapy has induced high response rates with a manageable safety profile (NCT03075696; Hutchings M, et al. ASH 2020). Rituximab in combination with gemcitabine and oxaliplatin (R-GemOx) is widely used for patients with R/R DLBCL who are not eligible for ASCT (Mounier N, et al. Haematologica 2013). Methods: GO41944 (NCT04408638) is a Phase III, open-label, randomized trial designed to evaluate the safety and efficacy of glofitamab plus gemcitabine and oxaliplatin (glofit-GemOx) vs R-GemOx in patients with R/R DLBCL. Eligible patients must be aged ≥ 18 years, have histologically confirmed DLBCL (excluding transformed indolent disease, and high-grade B-cell lymphoma (BCL) with MYC and BCL2 and/or BCL6 rearrangements), and have received ≥ 1 prior systemic therapies; patients who have failed only one prior line of therapy must not be eligible for high-dose chemotherapy followed by ASCT. Prior treatment with GemOx, R-GemOx or a CD20xCD3 bispecific antibody is not permitted. Patients are randomized 2:1 to receive up to eight 21-day cycles of either glofit-GemOx (intravenous [IV], followed by up to four cycles of glofitamab monotherapy) or R-GemOx (IV). A single dose of obinutuzumab is administered seven days prior to the first glofitamab administration. Randomization is stratified by number of prior lines of therapy and outcome of last systemic therapy (relapsed vs refractory). The primary objective is overall survival from time of randomization. Secondary efficacy objectives include progression-free survival, complete and overall response rates, duration of response, and time to deterioration in physical functioning and fatigue, and in lymphoma symptoms. Safety objectives comprise rate of adverse events, change from baseline in targeted vital signs and clinical laboratory test results, and tolerability. Pharmacokinetic, immunogenicity and biomarker endpoints will also be explored. The study started on February 17, 2021; an estimated enrollment of 270 patients by the study completion date of March 2022 is anticipated. Clinical trial information: NCT04408638.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yanchen发布了新的文献求助10
1秒前
1秒前
1秒前
寻绿完成签到,获得积分10
1秒前
元舒甜完成签到,获得积分10
1秒前
jkhjkhj完成签到,获得积分10
2秒前
十五完成签到,获得积分10
2秒前
书男完成签到,获得积分10
2秒前
菜菜完成签到 ,获得积分10
3秒前
li完成签到,获得积分10
3秒前
万能图书馆的应助被cfw采纳,获得10
3秒前
pingbaby完成签到 ,获得积分10
3秒前
3秒前
菲菲完成签到,获得积分10
4秒前
点点完成签到 ,获得积分10
4秒前
Wesley完成签到,获得积分10
5秒前
GU完成签到,获得积分0
5秒前
Rony发布了新的文献求助10
5秒前
科研通AI6.2的应助被qczm采纳,获得10
5秒前
打打的应助被哈哈w采纳,获得10
6秒前
6秒前
辛勤驳完成签到,获得积分10
6秒前
Xuz完成签到 ,获得积分10
6秒前
言诚开完成签到,获得积分10
7秒前
111完成签到,获得积分10
7秒前
健康的鸽子完成签到,获得积分10
7秒前
dagongren完成签到,获得积分0
7秒前
宁恕完成签到,获得积分10
7秒前
华清如发布了新的文献求助10
7秒前
晓世完成签到,获得积分10
7秒前
阿明完成签到 ,获得积分10
8秒前
啦啦完成签到,获得积分10
8秒前
kevin231的应助被落后酸奶采纳,获得10
8秒前
8秒前
zxp完成签到,获得积分10
9秒前
小美最棒完成签到,获得积分10
9秒前
缘分完成签到,获得积分0
10秒前
八八大发完成签到,获得积分10
10秒前
yang发布了新的文献求助10
10秒前
小鱼完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159212
求助须知:如何正确求助?哪些是违规求助? 9554678
关于积分的说明 21720538
捐赠科研通 7748887
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552092
邀请新用户注册赠送积分活动 2471464